Dashboard
Manage Tickers

ALLKAllakos Inc.

Nasdaq allakos.com


$ 1.20 $ -0.09 (-6.98 %)    

Friday, 10-May-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 1.2
$ 1.20
$ 0.00 x 0
$ 0.00 x 0
$ 1.18 - $ 1.21
$ 0.98 - $ 5.64
534,549
na
105.65M
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-06-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-05-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 03-14-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-29-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

allakos-q1-2024-gaap-eps-081-misses-044-estimate
Allakos Q1 2024 GAAP EPS $(0.81) Misses $(...
05/09/2024 20:54:22

Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.44) by ...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
05/01/2024 20:31:24

allakos-q4-eps-071-misses-047-estimate
Allakos Q4 EPS $(0.71) Misses $(0.47) Esti...
03/14/2024 20:05:06

Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.47) by ...

allakos-announced-a-poster-presentation-at-the-2024-american-academy-of-allergy-asthma--immunology-annual-meeting-the-poster-highlights-preclinical-data-detailing-ak006s-mechanism-of-action-and-ability-to-reduce-mrgprx2-induced-skin-inflammation
Allakos Announced A Poster Presentation At...
02/26/2024 12:18:09

Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages ...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
02/14/2024 13:05:52

allakos-announced-the-publication-of-new-scientific-results-in-allergy-the-preclinical-research-found-that-ak006-agonist-siglec-6-antibody-impacts-mast-cell-function-by-interacting-with-multiple-activating-receptors-and-key-signaling-molecules
Allakos Announced The Publication Of New S...
02/12/2024 12:32:26

jmp-securities-maintains-market-outperform-on-allakos-lowers-price-target-to-3
JMP Securities Maintains Market Outperform...
01/17/2024 19:16:22

JMP Securities analyst Jonathan Wolleben maintains Allakos (NASDAQ:ALLK) with a Market Outperform and lowers the price targe...

netflix-to-rally-over-13-here-are-10-top-analyst-forecasts-for-wednesday
Netflix To Rally Over 13%? Here Are 10 Top...
01/17/2024 13:19:50

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
01/17/2024 13:05:58

barclays-maintains-underweight-on-allakos-lowers-price-target-to-1
Barclays Maintains Underweight on Allakos,...
01/17/2024 11:17:10

Barclays analyst Carter Gould maintains Allakos (NASDAQ:ALLK) with a Underweight and lowers the price target from $1.5 to $1.

jefferies-downgrades-allakos-to-hold-lowers-price-target-to-15
Jefferies Downgrades Allakos to Hold, Lowe...
01/17/2024 10:56:00

Jefferies analyst Kevin Strang downgrades Allakos (NASDAQ:ALLK) from Buy to Hold and lowers the price target from $6 to $1.5.

gold-down-1-pnc-financial-posts-upbeat-earnings
Gold Down 1%; PNC Financial Posts Upbeat E...
01/16/2024 19:14:27

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 350 points on Tuesday. The Dow tra...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
01/16/2024 17:31:05

crude-oil-edges-lower-morgan-stanley-posts-upbeat-revenue
Crude Oil Edges Lower; Morgan Stanley Post...
01/16/2024 16:53:08

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday. The ...

trial-setback-allakos-drops-lead-skin-disorder-candidate-cuts-workforce-by-50
Trial Setback: Allakos Drops Lead Skin Dis...
01/16/2024 15:33:07

Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous ur...

dow-dips-200-points-goldman-sachs-earnings-top-views
Dow Dips 200 Points; Goldman Sachs Earning...
01/16/2024 14:49:46

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market ...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
01/16/2024 13:05:52

allakos-plans-not-to-pursue-further-development-of-lirentelimab-will-focus-on-ak006-clinical-development-and-additional-preclinical-programs
Allakos Plans Not To Pursue Further Develo...
01/16/2024 12:03:08

allakos-announced-topline-data-from-its-phase-2-trial-for-lirentelimab-in-atopic-dermatitis-atlas-and-phase-2b-study-in-chronic-spontaneous-urticaria-maverick-the-studies-did-not-meet-their-primary-endpoints
Allakos Announced Topline Data From Its Ph...
01/16/2024 12:02:32

trading-halt-halted-at-65531-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:31 a.m. ET - ...
01/16/2024 11:55:35

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION